Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
By now you've heard the news: Canopy Growth (NYSE:CGC) has confirmed rumors that it intends to acquire U.S. vertically integrated cannabis company Acreage Holdings in a deal valued at $3.4 billion -- the largest acquisition in marijuana history. Based on this one single fact (and a corollary assumption), this morning analysts at GMP Securities upgraded Canopy Growth stock to buy and assigned a new price target of 72 Canadian dollars, or nearly $54 a share.
Here's what you need to know.
What Canopy (might) buy
Let's start with the details of the deal to acquire Acreage, beginning with the fact that this is not a done deal just yet. As TheFly.com explained in a report last week, Canopy is working around NYSE and Toronto Stock Exchange restrictions on listing companies that engage in the currently federally illegal practice of selling marijuana in the U.S by buying the right to buy Acreage at a later date.
Specifically, Canopy wants to pay Acreage $300 million today for the right to acquire all of Acreage sometime in the future, in exchange for which Canopy will trade 0.5818 shares of Canopy for each share of Acreage on that later date, raising the total implied value of the acquisition to the aforementioned $3.4 billion.
What exact date that will be will depend on when the U.S. Congress changes its laws to legalize the sale of marijuana across the length and breadth of the United States.
Mark your calendars
When will that time come? Apparently, 2027 -- or sooner.
Upgrading Canopy this morning, GMP noted that "there is a high likelihood that federal legalization occurs within the 90-month expiry clause," as quoted in a write-up on StreetInsider.com (subscription required). (The analyst mentions this, by the way, because in Canopy's press release on the Acreage acquisition, it notes that "if the Triggering Event [i.e., legalization] is not satisfied or waived within 90 months from the payment of the Up-Front Cash Premium, the Agreement will terminate.") Thus, it seems Canopy's deal with Acreage is conditioned upon U.S. federal legalization happening within the next 7.5 years -- or basically, by the end of 2027.
And GMP may be right about legalization happening soon. As my fellow Fool.com contributor Keith Speights pointed out last week:
The prospects of U.S. marijuana legalization certainly appear to be better than ever. The STATES (Strengthening the Tenth Amendment Through Entrusting States) Act, which would federally recognize legalization of cannabis in states that have done so, has been introduced into the U.S. House of Representatives and the Senate. With Democrats controlling the House, passage of the legislation in the chamber seems likely. That could create tremendous pressure on the GOP to allow a vote to be held on the STATES Act in the Senate.
What it means to Canopy Growth investors
Acting on this belief, GMP Securities is going ahead and including Acreage in its updated valuation on Canopy Growth stock. (It's not yet including Acreage in its near-term profits projections, however, as there's no firm guarantee on when Canopy will be able to complete its acquisition and begin benefiting from Acreage's revenue and profits streams.)
With that caveat, arguing that Acreage is worth "much more" as an integral part of Canopy "than as a stand-alone" entity, GMP assigns the hypothetical Canopy subsidiary a valuation of "22x consensus 2021 EBITDA of US$292m" -- or about CA$15 per Canopy share. Similar assumptions give the analyst a CA$56-per-share valuation for Canopy as it stands today -- thus, CA$72 for the combined business. (GMP apparently rounded that number up).
Of course, to achieve this valuation, GMP had to do a fair amount of guesswork. As confirmed by data from S&P Global Market Intelligence, neither Acreage nor Canopy Growth are currently profitable, with the former reporting trailing-12-month EBITDA losses of $22 million, and the latter posting losses of $311 million. Nonetheless, GMP is projecting that if Canopy grows as expected, it will ultimately enjoy a 28% share of the Canadian recreational marijuana market and earn 28% EBITDA margin on its revenue.
As for today, however, with Canopy Growth priced at 118 times sales (trailing sales of the two companies, combined, amounted to less than $130 million over the last 12 months), I can only call Canopy's current valuation -- much less GMP's price target -- speculative in the extreme.